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Abstract
Background: The diagnostic tools to predict the prog-
nosis in patients suffering from breast cancer (BC)
need further improvements. New technological
achievements like the gene profiling of circulating tu-
mour cells (CTC) could help identify new prognostic
markers in the clinical setting. Furthermore, gene ex-
pression patterns of CTC might provide important in-
formations on the mechanisms of tumour cell metas-
tasation.
Materials and Methods: We performed realtime-PCR
and multiplex-PCR analyses following immunomag-
netic separation of CTC. Peripheral blood (PB) sam-
ples of 63 patients with breast cancer of various
stages were analyzed and compared to a control group
of 14 healthy individuals. After reverse-transcription,
we performed multiplex PCR using primers for the
genes ga733.3, muc-1 and c-erbB2. Mammaglobin1, spdef
and c-erbB2 were analyzed applying realtime-PCR.
Results: ga733.2 overexpression was found in 12.7% of
breast cancer cases, muc-1 in 15.9%, mgb1 in 9.1% and
spdef in 12.1%. In this study, c-erbB2 did not show any
significant correlation to BC, possibly due to a highly
ambient expression. Besides single gene analyses, gene
profiles were additionally evaluated. Highly significant
correlations to BC were found in single gene analyses
of ga733.2 and muc-1 and in gene profile analyses of
ga733.3*muc-1 and GA7 ga733.3*muc-1*mgb1*spdef.
Conclusion: Our study reveals that the single genes
ga733.3, muc-1 and the gene profiles ga733.3*muc-1 and
ga733.3*3muc-1*mgb1*spdef can serve as markers for the
detection of CTC in BC. The multigene analyses
found highly positive levels in BC patients. Our study
indicates that not single gene analyses but subtle pat-
terns of multiple genes lead to rising accuracy and low
loss of specificity in detection of breast cancer cases.
Key words: Mamma carcinoma, pcr, gene profile
Abbreviations: BC = breast cancer; CTC = circulating
tumour cells; PB = peripheral blood; c-erbB2 = cellular
avian erythroblastosis homologue B2; ga733.2 = major
gastrointestinal tumour-associated protein; muc-1 =
mucin-1; mgb-1 = mammaglobin-typ1; mRNA = mes-
senger RNA; PCR = polymerase chain reaction; RT-
PCR = reverse transcriptase polymerase chain reac-
tion; RT = reverse transcriptase; spdef = SAM pointed
domain-containing ETS transcription factor; FD =
First Diagnosis; RD = Relapse Disease; ABCD= Ad-
nagen breast cancer detect kit; ABCS= Adnagen
breast cancer select kit
INTRODUCTION
Circulating tumour cells (CTC) have been shown to
play a major role in breast cancer (BC) tumour biology
and may have a prognostic value in patients with
metastatic disease [1] Primary tumour architectural
characteristics may define its ability to metastize [2;
45-48]. Weak cell-cell connections lead to the dissemi-
nation of tumour cells via blood and lymph vessels
[3]. Tumour cells entering the circulation depend on
the organ microenvironment in order to be able to
colonize tissues and to proliferate [4-7].
Altered gene expression is held responsible for a
transformed behaviour of tumour tissue [8-11] and
may distinguish CTC from healthy cells [12-13]. How-
ever, it remains unclear which genes allow a specific
detection of CTC. Furthermore, inter- individual vari-
ations in gene expression levels due to certain genetic
polymorphism additionally challenge these investiga-
tions.
The relatively small amount of CTC in PB of can-
cer patients led to the development of improved de-
tection systems and cell enrichment [1, 14]. Several ap-
proaches of immunomagnetic enrichment of CTC in
samples of PB have been investigated [15-17]. Beads
coated with monoclonal antibodies (mcAb) against ep-
ithelial surface proteins achieve a precise detection and
extraction of epithelial and carcinoma cells from PB.
Subsequently, enriched CTC can be detected by re-
verse transcriptase polymerase chain reaction (RT-
PCR) of altered marker genes putatively supposed to
be tumour predictive. Several investigations have
analysed various genetic markers to detect CTC.
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(muc-1), a gene coding for a polymorphic epithelial sur-
face phosphoprotein. This study included both patients
with benign breast disease and advanced BC and indi-
cated a significant correlation between the presence of
muc1-positive cells and tumour staging. [18]. These
findings were reproduced by Felton et al. showing simi-
lar results in patients with advanced disease [19].
ga733.3 (TACSTD1, Ep-CAM), a gene responsible
for epithelial cell-cell adhesion by encoding a surface
glycoprotein, is regarded as being present exclusively
on epithelial cells [20]. Its use as a tumour marker has
been controversially discussed [21]. Nevertheless Rao
et al. [22] could demonstrate a decreased expression of
ga733.2 in CTC as compared to primary tumour cells.
This might indicate that decreased levels of this pro-
tein are crucial to the loss of cell adhesion which al-
lows tumour cell to access the circulation. Notably
Watson et al. documented an overexpression of
SCGB2A2 (mammaglobin 1; MGB-1), a polypeptide
member of the uteroglobin family, in BC [23-24].
Mammaglobin1-RT-PCR determination in PB was sug-
gested as an adjunct to serum tumour markers by Lin
et al. since the sensitivity sole mgb1 in RT-PCR assays
was considered as not convincing. Further studies
compared the positivity of fresh BC tissue and PB
[25]. Furthermore, a correlation between the frequen-
cy of mgb1 overexpression in PB and the tumour stage
of BC was described by Cerveira et al. [26].
Ghadersohi et al. described a strong expression of
spdef in RT-PCR assays of BC tissues. Further investi-
gations showed a superior tumour-association of this
marker as compared to other cancer-associated mole-
cules [27-30].
The purpose of the present study was to character-
ize CTC in PB of BC patients applying a commercially
available system that targets the above mentioned
genes.
MATERIAL AND METHODS
This study was reviewed and approved by the institu-
tional human subjects committee. BC patients and
healthy individuals serving as controls provided in-
formed-consent to all procedures.
STUDY DESIGN
Our study included 63 BC patients and 14 healthy
controls. Patients ages ranged from 33 to 81 years with
a median of 60 years. The age of controls varied be-
tween 24 and 61 with a median of 41.5 years. Fifty pa-
tients presented with first diagnosis (FD) of BC and
13 had relapse disease (RD) at the time of the PB col-
lection. Disease staging according to the American Joint
Committee on Cancer (AJCC) is summarized in Table 1.
The median time interval between surgical treatment
and study enrollment was 2.5 months for FD and 60
months for relapse disease (RD).
CELL SEPARATION
Venous blood samples were collected in EDTA Vacu-
tainer Tubes (Becton Dickinson, NJ USA) and processed
within 2 hours using the immunomagnetic separation
technique Adnagen Breast Cancer Select Kit (ABCS) (Ad-
nagen, Langenhagen, Germany) following the manufactur-
er’s instructions. This technique is based on an im-
munological selection of shedded non-haematological
cells using antibodies, directed against epithelial and
probably malignant surface antigens. Briefly, a combi-
nation of antibodies is loaded with magnetic particles
and preserved in sodium-acid. Antibodies against
ga733.3 and two different antibodies against epitopes
of mucin-1 were used.
Before applying the blood samples, the immuno-
magnetic beads underwent three washing steps in a 1.5
ml tube using 1 ml PBS (Gibco Invitrogen, Karlsruhe Ger-
many). Each step contained a bead separation in a mag-
netic bar system (MPC-S of Dynal). Subsequently 100
ﾵl of immunomagnetic beads were added to 5 ml of
blood samples without any additions. Samples, includ-
ing beads, were inserted in a tube rotator for 2 hours
at 20 rounds per minute (rpm) and room temperature
(RT).
Using a larger magnetic bar system (MPC-L of Dy-
nal Invitrogen, Karlsruhe Germany), bead-loaded cells were
accumulated on the MPC-L side. Subsequently, super-
natants were removed cautiously and PBS (5 ml) was
added. PBS addition, MPC-L hold and removing of
supernatants were repeated two times. At the end of
this step, bead-cell-complexes were resuspended in
1ml of PBS and inserted in MPC-S. Supernatants were
removed once more and complexes were resuspended
in 200 ﾵl of ABCS lysis/binding buffer. Finally, sam-
ples were inserted into MPC-S again. This time, super-
natants, including cell lysates with native mRNA, were
saved and stored at -20 ﾰC.
ABCD was applied for RT and PCR steps of stored
cell lysates. This kit contains lysis/binding buffer, oli-
go(dT)-25 beads, buffers A and B, tris-HCl and
Primermix. Additionally used kits included Sensiscript
Reverse Transcription Kit and HotStarTaq Mastermix Kit
(Qiagen) and Recombinant RNAsin (RNAse-Inhibitor
Promega).
Briefly, oligo(dT)-coated beads (ABCD Dynabeads),
targeting certain mRNA, were inserted in MPC-S and
supernatants were removed. Beads were washed in ly-
sis/binding buffer. This step was repeated once and 20
ﾵl of dynabead was aliquoted subsequently to each
sample of cell lysates. The mix of cell lysates and dyn-
abeads was placed on a tube rotator for 10 minutes at
20 rpm and RT. Samples were inserted in MPC-S and
supernatants were removed.
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Table1. Clinical Staging. 63 breast cancer patients presenting
with First Diagnosis (FD) or Relapse Disease (RD) were en-
rolled in this study. G represents disease staging according to
the American Joint Committee on Cancer (AJCC).
G12 3 Xʣ
FD 4 25 19 2 50
(%) 8% 50% 38% 4% 100%
RD 08 4 113
(%) 0% 61.5% 30.8% 7.7% 100%
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B and tris-HCl and inserted in MPC-S each time . Su-
pernatants were removed. Washing steps with buffer A
and B were processed twice, whereas tris-HCl was ap-
plied once.
After the final elimination of supernatants, we re-
suspended mRNA-bead-complexes in 29.5 ﾵl RNAse-
free water and incubated them in a thermomixer for 5
minutes at 650 rpm and 50 ﾰC.
REVERSE TRANSCRIPTION (RT)
Prepared RT-mix consisted of 4 ﾵl 10x buffer RT, 4 ﾵl
dNTPs, 2 ﾵl RT (Qiagen, Hilden Germany) and 0.5 ﾵl
RNAse inhibitor (Promega, Mannheim Germany) for each
sample of 29.5 ﾵl mRNA/bead-complexes. RNAse-
free water was used as control. Transcription was per-
formed in a thermocycler (Perkin Elmer 9600; 2ﾰC/
second) with following program:
37 ﾰC for 60 minutes – reverse transcriptase step
93 ﾰC for 5 minutes – inactivation step
cDNA suspension was stored on ice.
MULTIPLEX PCR
Multiplex PCR (mPCR) was executed using 25 ﾵl of
Hotstar Taq Mastermix (Qiagen, Hilden-Germany), 13 ﾵl
distilled water, 4 ﾵl PrimerMix Breast Detect (ABCD) and
8 ﾵl of cDNA suspension, RT-control, water as nega-
tive control or positive control (ABCD) respectively.
Primermix was a threefold combination of primers for
ga733.2 (383 bp), muc-1 (293 bp), c-erbB2 (270 bp) and
ʲ-actin (114 bp) as control gene41. The total volume
of 50 ﾵl was inserted in a thermocycler (Perkin Elmer
9600; 2°C/second) and PCR was performed with 2
ﾰC/second according to the following program:
1. 95ﾰC for 15 minutes – Taq activation
2. 94ﾰC for 1 minute
3. 60ﾰC for 1 minute
4. 72ﾰC for 1 minute
5. 72ﾰC for 10 minutes – final elongation
6. 4ﾰC
Steps 2 to 4 were repeated for 35 cycles. Finally,
DNA suspensions were stored at -20ﾰC. PCR products
were analyzed in bioanalyzer (2100 - bioanalyzer Agilent,
CA, USA) via DNA chips (version 25-1000bp). Re-
sults were registered according to the fluorescence and
via conversion in absolute cDNA concentration
(ng/ﾵl). As mentioned previously ʲ-Actin was chosen
as house keeping gene.
REALTIME-PCR
The expression of c-erbB2, mgb1 and spdef was deter-
mined quantitatively using high throughput real-time
RT-PCR applying an ABI PRISMﾮ 7900HT cycler
(AME Bioscience, Toroed Norway). GUSBL1 (beta-like glu-
curonidase 1) was chosen as housekeeping gene. Probes
were ordered as "ready to order" primer probe TaqMan gene
expression assays, (Hs00170433_m1 for c-erbB2,
HS00267190_m1 for mgb1, HS0017942_m1 for spdef,
Applied Biosystems, CA, USA). Each assay contained a
pair of amplification primers and an additional Taq-
Man MGB oligonucleotide probes with a 6-FAM fluo-
rescent dye linked to the 5ﾴend and one dark quencher
on the 3ﾴend with a minor groove binder protein, in-
creasing the probe melting temperature (Tm). Genes
were selected according to frequently appearing gene
expressions in our previous data (Affymetrix Chip Hg-
U133A, 22283 genes in 83 breast cancer profiles vs 5
normal breast profiles) [31].
The PCR was run in a 96-well plates at a total vol-
umes of 25ﾵl, containing the TaqMan Universal PCR
Master Mix (dNTP, buffer, ROX and the AmpliTaq-
Gold). The default thermal cycling protocol (as rec-
ommended by ABI) was used for all target genes and
the reference gene (initial step of 15 min at 95ﾰC for
the activation of the AmpliTaqGold and an amplifica-
tion cycle of 15 sec at 95ﾰC and 1 min at 60ﾰC for 40
cycles). Genes were quantified by determination of a
threshold cycle numbers (ct). One common threshold
was specified manually within the early exponential
phase of fluorescence increase and it was used for all
genes within one experiment. 'Transcriptase-minus'
and 'water-only' controls were included.
The Her-2/neu status of 84.1% of our patients was
determined routinely using immunhistochemistry (an-
tibody against Her-2/neu: polyclonal DAKO 1:250).
Staining results are classified into four levels according
to the manufacturer’s recommendation. Highly posi-
tive synthesis of Her-2/neu (≥ 2+) was observed in 20
cases of BC (20/53; 37.7%).
STATISTICAL EVALUATION
Statistical evaluation was performed using SPSS 11.5
for Windows (Microsoft Corp., SA, USA). Specific
amplifications both in mPCR and realtime-PCR were
registered in units specified for each gene and each
group of patients separately. Results were recorded in
dichotomized values. The threshold of dichotomized
compilation was predetermined at 0.1 ng/ﾵl for
mPCR according to manufacturer’s recommendation.
Realtime-PCR results with (ct) values below 41 cycles
were considered as positive. Afterwards, we searched
for correlations between cases of FD, RD and healthy
participants. Besides single gene evaluations‚, these
searches also included multiple gene evaluations. Sin-
gle-positive results were defined as samples that fea-
tured positive expressions for one gene, whereas
twofold-positive results were defined as samples that
featured positive expressions of at least two genes
[32]. Correlations were checked either by Pearson’s
two-sided ˇ2-test for dichotomized values or by Pear-
son’s bivariate correlation for values with two thresh-
olds. The level of significance was determined as p
<0.05.
RESULTS
EXPRESSION LEVELS OF ga733.2, muc-1 AND c-erbB2 IN
PB THROUGH mPCR
Positive absolute PCR products of BC patients ranged
from 0.1 to 8.4 ng/ml for ga733.3, from 0.12 to 6.3
ng/ml for muc-1 and from 0.13 to 1.1 ng/ml for c-erbB2.
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cations for ga733.3 (5/50; 10%), muc-1 (6/50; 12%)
and c-erbB2 (7/50; 14%).
Cases of RD exposed overexpression rates for
ga733.3 (3/13; 23.1%), muc-1 (4/13; 30.8%) and c-erbB2
(1/13; 7.7%). Healthy controls showed positive ex-
pressions for ga733.3 (1/14; 7.1%), muc-1 (1/14; 7.1%)
and c-erbB2 (7/14 ; 50%) (Fig. 1).
EXPRESSION LEVELS OF mgb-1, spdef AND c-erbB2 IN PB
THROUGH RT-PCR
4 samples of FD and 2 cases of RD had neither mgb1
specific nor non-specific transcription and were ex-
cluded from further examination. The same lack of
transcription was found in 2 cases of FD and 1 case of
RD concerning spdef. Hence we continued our investi-
gation including 55 patients (44 FD and 11 RD cases)
concerning mgb1 and 58 patients (46 FD and 12 RD
cases) concerning spdef. Results of remaining products
of patients ranged from 28 cycles to 39.5 cycles for
mgb1 and from 29.4 cycles to 40.9 cycles for spdef. Spe-
cific signals (< 41 ct) for mgb1 were observed in 2/44
(4.5 %) cases of FD and 3/11 (27.3 %) cases of RD,
whereas this value was 0/14 in healthy controls. spdef
was detectable in 5/46 (10.9 %) cases of FD, in 2/12
(16.7 %) cases of RD and in 0/14 healthy controls, re-
spectively. C-erbB2 expression was found in 11/50
(22%) cases of FD, in 5/13 (38.5%) cases of RD and
in 10/14 (71.4%) healthy controls. Results ranged
from 39.9 cycles to 33.5 cycles (Fig. 2).
VIEW OF MULTIPLE-POSITIVE CASES
The analyses of simultaneous gene expressions of
ga733.3, muc-1, spdef and mgb1 revealed 15 cases of BC
with a positive expression of at least one of these
genes. As results of mgb1 were available in 55 cases, we
limited this part of the investigation to this cohort of
patients. Nine out of 44 positive cases were found in
FD cases (9/44; 20.5%) and 6 out of 11 in RD cases
(6/11; 54.5%).
VIEW OF SIMPLE-POSITIVE EXPRESSION OF THE GENE
PROFILE ga733.2*muc-1*mgb1*spdef
The 15 participants of the BC group (15/55; 27.3%)
had at least one positive expression of the gene pat-
tern GA7 ga733.3*muc-1*mgb1*spdef. Nine cases
(20.5%) belonged to the FD cohort and 6 (54.5%) to
RD cohort. Healthy controls also demonstrated posi-
tive results in 2 cases (14.3%) (Fig. 3).
VIEW OF TWOFOLD-POSITIVE EXPRESSION OF THE
GENE PROFILE ga733.3*muc-1*mgb1*spdef
Regarding at least two positive gene expressions in the
pattern specified above, 10 cases (18.2%) of BC patients
and no healthy controls fulfilled this criterion. 6 posi-
tive cases were seen in the group of FD (6/44; 13.6%)
and 4 in the group of RD (4/11; 36.4%) (Fig. 3).
CORRELATION OF EXPRESSION RESULTS TO
HER-2/NEU LEVEL VIA IHC
Since we did not detect any significant correlation of
Her-2/neu status and c-erbB2 mRNA in the results of
our mPCR and realtime-PCR analyses, the investiga-
tion comparing Her-2/neu to other genes and respec-
tive gene profiles did not reach any significance.
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Fig. 1. ga733.3 and muc-1 expression. Multiplex pcr
analyses of ga733.2 and muc-1 in peripheral blood. The
“overall” panel refers to the patients with First Diagnosis
(FD) and Relapse Disease (RD) excluding healthy controls.
Fig. 2. spdef and mgb1 expression. Positivity for spdef and
mammaglobin1 in peripheral blood through RT-PCR. The
“overall” panel refers to the patients with First Diagnosis
(FD) and Relapse Disease (RD), excluding healthy controls.
Fig. 3. ga733.2*muc-1*mgb1*spdef expression. Simple positive
or two-fold positivity for the gene pattern ga733.2*muc-
1*mgb1*spdef. The “overall” panel refers to the patients with
First Diagnosis (FD) and Relapse Disease (RD), excluding
healthy controls.
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Today there is a growing interest in the gene character-
ization of CTC in BC, since it may provide important
information on the mechanisms for tumour cell
metastasation. We analyzed PB samples of BC patients
presenting at our gynaecology department. The goal
of our study was to determine marker genes with a
high sensitivity for the detection of CTC. For this aim,
we selected tools to detect CTC and to amplify DNA
of predetermined genes, which are potentially overex-
pressed in tumour cells. Based on data provided by re-
cent studies we used an immunomagnetic method to
select circulating carcinoma cells [33-34]. An adverse
effect on gene expression by application of direct im-
munomagnetic enrichment was excluded [35].
Several studies have described muc-1, c-erbB2 and
mgb1 as putative markers in BC. Yet, our not-preselect-
ed group of BC patients revealed a markedly lower
overall expression of muc-1 as compared to other re-
cent investigations [14-36]. Yet, tour results concern-
ing mgb1 match those of Grunewald et al. [37]. Never-
theless higher expressions of mgb1 (36.6%) in all
stages of BC as compared to healthy controls were de-
scribed by Lin et al. [38].
Additionally our study investigated ga733.3 and
spdef, which have not been described commonly in BC
cases, but which do possess putative marker character-
istics [20, 28-30, 39]. Notably, ga733.3 and spdef
showed nearly the same overall frequency of overex-
pression as the above mentioned cancer-associated
marker genes. To the best of our knowledge, investi-
gations of spdef in PB applying RT- and realtime PCR
analyses have not been described in the literature, yet.
Remarkably, the use of ga733.3 as marker was contro-
versially discussed in recent studies due to its minimal
basal expression in hematopoietic cells [21]. ga733.3
transcribes the surface molecule Ep-CAM in epithelial
cells and serves as target molecule in immunomagnetic
procedures of cell detection [41-42]. Thus, our study
includes both Ep-CAM as immunomagnetic target
transcript and ga733.3 as investigated gene using
mPCR.
Comparisons of controls and BC patient groups re-
vealed an increased frequency of ga733.3 (8/63 vs.
1/14), muc-1 (10/63 vs. 1/14), spdef (7/58 vs. 0/25)
and mgb1 (5/55 vs. 0/25). It is notable, that Zhong et
al. (1999) demonstrated a high frequency of ga733.3
expression in healthy subjects (40%; 16/40) [20].
However, this study did not include any immunomag-
netic processes to eliminate haematogenous cells. An-
other investigation of Rao et al. (2005) revealed a de-
crease of ga733.3 expression in CTC as compared to
ga733.3 expression in tumour tissues, proposing a
mechanism through which cells loose adhesion to en-
ter circulation. Yet, this study did not include control
subjects [22].
Muc-1 is described as a widely expressed gene in
cells of epithelial origin. The literature shows contro-
versial results regarding muc-1. On the one hand,
Raynor et al. (2002) demonstrated that muc-1 tran-
scribes a surface molecule, which was found in human
non-malignant cells. Hence, a putative marker feature
was denied in this investigation [43]. On the other
hand, Felton et al. (2004) verified muc-1 expression in
8 of 9 advanced cases of BC, whereas only 1 of 11
healthy controls showed a positive expression. More-
over, they confirmed the expression of muc-1 in non-
malignant peripheral lymphocytes [44]. Our investiga-
tion revealed 15.9% positive expression in BC sam-
ples but only 7% in healthy controls. Notably, former
approaches did not include any immunomagnetic sep-
aration method and were performed in restricted
numbers of patients. Spdef (SAM pointed domain-contain-
ing ETS transcription factor, synonym PDEF) is a tran-
scription factor involved in processes like cell prolifer-
ation, differentiation and invasion. It is mainly ex-
pressed in tissues with high fraction of epithelial cells.
Recently, Ghadersohi et al. (2001) described higher
expression of spdef in BC tissue as compared to
healthy breast specimens [28]. In line with those re-
sults, we did not observe any positive results in the
control group.
Most notably, in 2005, Van’t Veer et al. emphasized
the importance of gene expression profiling of multi-
ple genes in BC, since single or double gene determi-
nation did not show satisfactory accuracy [45]. Here
we demonstrate, that method-overlapping (mPCR and
realtime-PCR) grouping of 4 genes, ga733.3, muc-1,
spdef and mgb1 exposes a positive result in 23.8% of
our BC patient population. Fourfold profile (ga733.3*
muc-1*spdef*mgb1) of controls levelled off at 14.3%.
To the best of our knowledge, our study represents
the first investigation of fourfold gene profiles report-
ed in the literature.
Taken together, our study shows that the single
genes ga733.3, muc-1 and the gene profiles ga733.3*
muc-1 and ga733.3*2muc-1*mgb1*spdef can serve as
markers for the detection of CTC in BC. Multigene
analyses revealed highly positive levels in BC patients.
Our study indicates that not single gene analyses but
subtle patterns of multiple genes leads to rising accu-
racy and low loss of specificity in detection of BC cas-
es
Yet, further studies are needed to better character-
ize CTC and to better understand metastatic processes
in BC. Prospective studies with a larger patient popu-
lations and investigations of other target genes may
identify aggressive profiles of BC and may influence
therapeutic decisions.
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